Adelaide
Clinical Trials
GPN Vaccines is developing vaccines to protect adults and children from the world’s most deadly pathogens.
Our lead product, Gamma-PN, has been shown to be safe, well-tolerated, and able to induce antibodies to all pneumococcal strains in 120 healthy volunteers aged 50-69. Future clinical trials will continue to assess the safety and effectiveness of Gamma-PN in children and the elderly, who are most susceptible to potentially life-threatening pneumococcal infections.
Upcoming Trials
GPNV-006
About GPNV-006
GPNV-006 is a Phase 1, randomised, active-controlled, blinded, dose-ranging study of the safety, tolerability, and immunogenicity of Gamma-PN3 in participants 70 and older.
Please note GPN Vaccines is not recruiting participants directly and all inquiries for involvement must be made via CMAX Fusion.
Are you eligible?
If you are over 70, living in Adelaide and generally in good health, you may be eligible to participate.
There are many criteria to join a clinical trial and we recommend discussing your eligibility with your GP.
CLICK HERE FOR MORE INFORMATION